FlowXL System: FlowXL Flowmeter and compatible Flowprobes and Flowsensors
Transonic Systems, Inc. · Decision date Oct 27, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-10-27 for K261714, the FlowXL® System: FlowXL Flowmeter and compatible Flowprobes and Flowsensors, submitted by Transonic Systems, Inc. of Ithaca, NY. The filing was received 05/26/2026 as a traditional 510(k) under regulation 870.2100, product code DPW, with the Cardiovascular specialty and review panel. SESE means the submission was cleared to market; it is not a PMA approval.
The record identifies the device as a blood flowmeter system with compatible probes and sensors, but the public summary fields do not describe the specific components, changes, or performance data reviewed. The summary document is linked but its contents are not included here, so the basis for the equivalence finding remains unknown. The same decision appears in FDA's final-decision listing dated 27 Oct 2026.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 27, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261714
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Transonic Systems, Inc.
- Product code
- DPW
- Decision code
- SESE
- Decision date
- Oct 27, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Flowmeter, Blood, Cardiovascular.
- Applicant
- Transonic Systems, Inc.
- Product code
- DPW
- FDA device class
- 2
FDA decision timeline
K261714 received
Application receipt date recorded by FDA.
K261714 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Transonic Systems, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Ithaca, NY
Sources and methodology
- Original FDA record: K261714
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records